$599

Gubra Receives Milestone Payment from AbbVie; Caliway Advances Lipolysis Drug

Two cardiometabolic-related news items have been observed: Gubra received a $50M milestone payment from AbbVie (view press release), and Caliway Biopharmaceuticals received IND clearance and IRB approval for its small molecule lipolysis drug (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here